Results 171 to 180 of about 62,929 (228)

Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas

International Journal of Cancer, Volume 158, Issue 12, Page 3217-3231, 15 June 2026.
What's new? Colorectal neuroendocrine carcinoma (CR‐NEC) is a rare digestive neuroendocrine neoplasm that frequently exhibits an adenocarcinoma component. Nonetheless, the underlying biology of CR‐NEC remains poorly understood. This study examined molecular and clinical features and palliative chemotherapy outcomes of metastatic CR‐NEC, with comparison
Siren Morken, Seppo W. Langer, Geir Olav Hjortland, Anna Sundlöv, Eva Hofsli, Morten Ladekarl, Elizaveta Tabaksblat, Lene Weber Vestermark, Johanna Svensson, Ulrich Knigge, Luís Nunes, Bengt Glimelius, Per Pfeiffer, Kristine Aasebø, Jörg Assmus, Erik Vassella, Inger Marie Bowitz Lothe, Anne Couvelard, Aurel Perren, Stian Knappskog, Halfdan Sorbye   +20 more
wiley   +1 more source

Carcinoembryonic Antigen Flare Under Oxaliplatin-Based Chemotherapy Predicts Benefit from Nivolumab in Metastatic Microsatellite-Stable Colorectal Cancer - A Post Hoc Analysis of METIMMOX Trial Data. [PDF]

Immunotargets Ther
Meltzer S, Landmark SS, Šaltytė Benth J, Negård A, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Flatmark K, Ree AH.   +10 more
europepmc   +1 more source

Antiviral regulator TRIM25 as a prognostic marker of better survival in Merkel cell carcinoma: Association with MCPyV status

International Journal of Cancer, Volume 158, Issue 12, Page 3268-3278, 15 June 2026.
What's new? TRIM25 is known for its role in antiviral immunity and association with poor prognosis in various cancers. This study reveals an association between high TRIM25 expression and Merkel cell polyomavirus positivity in Merkel cell carcinoma.
Klaus W. Fagerstedt, Sami Kilpinen, Johanna Arola, Benjamin Z. Sundqvist, Tom Böhling, Leif C. Andersson, Harri Sihto   +6 more
wiley   +1 more source

Placebo Response in Phase II-III Symptom Intervention Studies: A Focus on Chemotherapy-Induced Peripheral Neuropathy and Associated Neuropathic Pain. [PDF]

Cancers (Basel)
Zahrieh D, Satele D, Haamankuli H, Wang XS, Le-Rademacher JG, Lee M, Liu H, Diaz-Cobo J, Shen SE, Chow S, Lustberg M, Ruddy KJ, Smith EML.   +12 more
europepmc   +1 more source

Efficacy and immunogenic effects of Tumor Treating Fields (TTFields) in preclinical models of pancreatic ductal adenocarcinoma, with and without gemcitabine/nab‐paclitaxel

International Journal of Cancer, Volume 158, Issue 12, Page 3091-3100, 15 June 2026.
What's new? Adaptive immune responses are typically limited in pancreatic ductal adenocarcinoma, resulting in minimal efficacy of immune checkpoint inhibitors. Tumor Treating Fields (TTFields) therapy, which uses low‐intensity intermediate‐frequency electric fields to disrupt cancer cell processes, has been approved for certain cancers.
Tal Kan, Tharwat Haj Khalil, Yiftah Barsheshet, Tali Voloshin, Lilach Koren, Bella Koltun, Cfir David, Kerem Wainer‐Katsir, Avital Vorontsova, Boris Brant, Simona Zisman‐Rozen, Hila M. Ene, Roni Frechtel‐Gerzi, Shay Cahal, Anat Klein‐Goldberg, Lena Lifshitz, Efrat Zemer Tov, Mai Shai, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti   +21 more
wiley   +1 more source

Multi-omics analysis of patient-derived organoids reveals that E3 ligase COP1 promotes liver metastasis and oxaliplatin resistance in colorectal cancer through LUZP1 degradation and MYL9 phosphorylation. [PDF]

Exp Hematol Oncol
Zhang R, Luo W, Zhou Q, Liang D, Hao Y, Chen F, Qiu Y, Cao Y, Shan Z, Zhang Y, Li Q, Cai S, Luo D, Mo S, Ma B, Li X.   +15 more
europepmc   +1 more source

PHGDH phosphorylation mediated by WNK1 serves as a dual marker of metabolic vulnerability and responsiveness to oxaliplatin treatment. [PDF]

Proc Natl Acad Sci U S A
Fang S, Jin G, Yan M, Song Y, Zhao S, Zhang C, Shao Y, Zhao K, Liu M, Wang Z, Jia X, Guo Q, Guo M, Wang M, Guo Z, Dong Z.   +15 more
europepmc   +1 more source

Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial.

JAMA Netw Open
Wang X, Yan O, Zhou J, Wen F, Shen Y, Li Z, Li Q, Wang W, Cai X, Tan S, Wang Z, Qiao Q, Cao D, Qiu M, Liu J, Gou H, Liu M, Yi C, Yang Y, Zhu Q, Luo D, Zhao Y, Chen Y, Wang S, Wang Q, Cheng K, Ren M, Liu X, Xu F, Bi F.   +29 more
europepmc   +1 more source

Advances in research on circadian rhythms and colorectal cancer. [PDF]

BMC Med Genomics
Jia L, Zhu M, Wu X, Zheng W, Zhang Y, Xiao J.   +5 more
europepmc   +1 more source

Comparative efficacy and safety of systemic therapies in transplant-eligible and ineligible relapsed/refractory large B-cell lymphoma: a Bayesian network meta-analysis. [PDF]

Transl Cancer Res
Huang L, Chen K, Wang M, Guo C, Li Y, Yu Q, Liu Z, Li Z.   +7 more
europepmc   +1 more source